Trial Outcomes & Findings for Eltrombopag for Thrombocytopenia in Patients With Relapsed Multiple Myeloma (NCT NCT01484314)
NCT ID: NCT01484314
Last Updated: 2017-03-15
Results Overview
To determine the proportion of patients with relapsed multiple myeloma in whom eltrombopag maintains platelet counts at \> 90% of baseline platelet counts with no more than 4 units of platelet transfusions at day 1 of Cycle 3 of chemotherapy
TERMINATED
PHASE2
1 participants
2 years
2017-03-15
Participant Flow
Participant milestones
| Measure |
Migration Arm
Administration of eltrombopag to support platelets during chemotherapy
Eltrombopag: 100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
|
|---|---|
|
Overall Study
STARTED
|
1
|
|
Overall Study
COMPLETED
|
1
|
|
Overall Study
NOT COMPLETED
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Terminated with 1 patient enrolled; no data due to patient privacy.
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 2 yearsPopulation: Terminated with 1 patient enrolled; no data due to patient privacy.
To determine the proportion of patients with relapsed multiple myeloma in whom eltrombopag maintains platelet counts at \> 90% of baseline platelet counts with no more than 4 units of platelet transfusions at day 1 of Cycle 3 of chemotherapy
Outcome measures
Outcome data not reported
PRIMARY outcome
Timeframe: 2 yearsPopulation: Terminated with 1 patient enrolled; no data due to patient privacy.
To determine whether eltrombopag administration results in an increased number of participants with adverse events.
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 2 yearsPopulation: Terminated with 1 patient enrolled; no data due to patient privacy.
To assess whether eltrombopag decreases the incidence of grade 3/4 thrombocytopenic events by day 1 of Cycle 3 of chemotherapy
Outcome measures
Outcome data not reported
Adverse Events
Migration Arm
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Dr. Nancy Berliner
Brigham and Womens Hospital/ Dana Farber Cancer Institute
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place